

Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc.

Novo Nordisk Inc. has recalculated its 340B ceiling prices for the period Q4 2023 for the products listed below due to revisions made to its Medicaid pricing data. Novo Nordisk Inc. has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about Novo Nordisk Inc.'s recalculation affecting certain 340B Covered Entities for the impacted products.

Novo Nordisk Inc. has determined the credit amount owed to each affected Covered Entity. Novo Nordisk Inc will be coordinating with its wholesalers to issue refunds to each affected Covered Entity. Refunds will be issued to a Covered Entity's validated wholesaler pharmacy account when one can be identified.

	Product Description
00169-7201-01	NOVO7 1MG MIX PRO
00169-7202-01	NOVO7 2MG MIX PRO
00169-7205-01	NOVO7 5MG MIX PRO
00169-7208-01	NOVO7 8MG MIX PRO
00169-8100-01	ESPEROCT 1000 IU
00169-8150-01	ESPEROCT 1500 IU
00169-8200-01	ESPEROCT 2000 IU
00169-8300-01	ESPEROCT 3000 IU
00169-8500-01	ESPEROCT 500 IU

If a Covered Entity believes it is due a refund and has not seen a credit to its wholesaler account by February 19, 2024, it may contact Novo Nordisk Inc., at NNIBIDNOTIFICATION@novonordisk.com.